Nuffield Orthopaedic Centre

Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)

Objectives PsA affects ~20-30% of patients with PsO, causing articular inflammation and impaired quality of life. ICO, a novel targeted oral peptide that binds IL-23 receptor, showed greater clinical response rates vs placebo and a favorable safety profile in moderate-to-severe p...

Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty

Aims Obesity and diabetes are risk factors for developing osteoarthritis and associated with worse outcomes following total hip (THA) and total knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1as) improve glycaemic control and promote weight loss. The aim...